We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00674960
Recruitment Status : Unknown
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
First Posted : May 8, 2008
Last Update Posted : August 17, 2009
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.

Brief Summary:
Pick's disease, also known as Pick disease,or FTD is a rare fronto-temporal neurodegenerative disease. This study will investigate the use of far infrared radiation for the control, management and treatment of Pick's disease.

Condition or disease Intervention/treatment Phase
Pick Disease of the Brain Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Phase 1

Detailed Description:

This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)
Study Start Date : May 2008
Estimated Primary Completion Date : May 2009
Estimated Study Completion Date : October 2009


Arm Intervention/treatment
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation (5μm to 20μm wavelength)



Primary Outcome Measures :
  1. Therapy for FTD patients [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Rehabilitation of FTD Patients [ Time Frame: 1 Year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • People with Pick's Disease

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674960


Locations
Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Investigators
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.

Responsible Party: : Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier: NCT00674960     History of Changes
Other Study ID Numbers: GAAD-FD-CTP1
First Posted: May 8, 2008    Key Record Dates
Last Update Posted: August 17, 2009
Last Verified: August 2009

Keywords provided by GAAD Medical Research Institute Inc.:
Brain Atrophy, Circumscribed Lobar
Circumscribed Lobar Atrophy of the Brain
Lobar Atrophy (Brain)
Pick Disease
Pick's Disease
Picks Disease of Brain

Additional relevant MeSH terms:
Frontotemporal Dementia
Pick Disease of the Brain
Dementia
Aphasia, Primary Progressive
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Frontotemporal Lobar Degeneration
TDP-43 Proteinopathies
Neurodegenerative Diseases
Proteostasis Deficiencies
Metabolic Diseases
Aphasia
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms